In biomedicine, much of the information generated is made publicly
available by and to the scientific community. These open data resources are
attracting significant attention, as the pharmaceutical industry finds
itself continuously under pressure to speed up the costly process of drug
Imagine this: The key to better cancer treatments is within reach, based
on patterns from data that is scattered across various locations all over
the world. This data could be digitalised, labelled, collected, stored and
interpreted. However, this data belongs to a countless number of
individuals – and their right to data privacy weighs just as much as
the dream of curing a lethal disease.
When we want to grasp the subjective experiences of others, we count on
their verbal accounts. Limited to language, quantifying how something feels
for an individual is very hard. It is even more arduous for altered states
of consciousness where descriptions become somewhat
In idalab seminar #10, we turn to the field of Precision Medicine. Dr.
Nicole Krämer from Staburo GmbH will give a talk on how Data Science can
help physicians to predict a patient’s reaction to a certain
treatment in advance.
The next idalab seminar will take place on Friday April 27th at 5pm, as
always in our office at Potsdamer Straße 68. We will host a talk by
Benjamin F. Maier, PhD student at the Robert Koch Institute and freelance
Open data in biomedicine is a gold mine that can strengthen innovation
in pharmaceutical R&D. In combination with the right analytics, public
data helps identify therapeutic targets and ligands, enhance clinical
development, and boost portfolio management efficiency. The challenge is to
purposefully integrate abundant and heterogeneous data scattered across
Data science projects are successful when they produce actionable
results over several years. Since databases constitute the foundation of
those endeavours, their selection is highly strategic, and the biomedical
field is no exception to that rule.